suramin has been researched along with Bone Cancer in 11 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin has in the last two decades been used as salvage therapy in some cancers." | 5.32 | Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro. ( Blahovec, H; Trieb, K, 2003) |
| "Suramin is known to inhibit the growth of malignant prostate carcinoma cells in vitro." | 2.67 | Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. ( Choyke, P; Cooper, M; Dawson, N; LaRocca, R; Myers, C; Stein, C; Steinberg, S; Uhrich, MM; Walther, MM; Weiss, G, 1992) |
| "Metastatic prostate cancer is a leading cause of cancer-related death in men." | 2.40 | Treatment options in androgen-independent prostate cancer. ( Lara, PN; Meyers, FJ, 1999) |
| "Suramin has in the last two decades been used as salvage therapy in some cancers." | 1.32 | Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro. ( Blahovec, H; Trieb, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (81.82) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trieb, K | 1 |
| Blahovec, H | 1 |
| Kantoff, PW | 1 |
| van Rijswijk, RE | 1 |
| Cvitkovic, E | 1 |
| Wagstaff, J | 1 |
| Myers, CE | 1 |
| Kloen, P | 1 |
| Jennings, CL | 1 |
| Gebhardt, MC | 1 |
| Springfield, DS | 1 |
| Mankin, HJ | 1 |
| Scotlandi, K | 3 |
| Benini, S | 3 |
| Nanni, P | 2 |
| Lollini, PL | 3 |
| Nicoletti, G | 1 |
| Landuzzi, L | 1 |
| Serra, M | 2 |
| Manara, MC | 3 |
| Picci, P | 3 |
| Baldini, N | 3 |
| Chano, T | 1 |
| Rizzi, S | 1 |
| Lara, PN | 1 |
| Meyers, FJ | 1 |
| Cerisano, V | 1 |
| Mercuri, M | 1 |
| Scher, HI | 2 |
| Curley, T | 2 |
| Yeh, S | 2 |
| Tong, W | 1 |
| O'Moore, PV | 1 |
| Larson, S | 1 |
| Iversen, JM | 1 |
| O'Dell, M | 1 |
| Larson, SM | 1 |
| Myers, C | 1 |
| Cooper, M | 1 |
| Stein, C | 1 |
| LaRocca, R | 1 |
| Walther, MM | 1 |
| Weiss, G | 1 |
| Choyke, P | 1 |
| Dawson, N | 1 |
| Steinberg, S | 1 |
| Uhrich, MM | 1 |
4 reviews available for suramin and Bone Cancer
| Article | Year |
|---|---|
New agents in the therapy of hormone-refractory patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Mitoxantrone; Prostate | 1995 |
Treatment options in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antibodies, Monoclonal; Antineoplastic Agents; Anti | 1999 |
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; | 1992 |
Therapeutic alternatives for hormone-refractory prostatic cancer.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Humans; Immunother | 1992 |
2 trials available for suramin and Bone Cancer
| Article | Year |
|---|---|
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; | 1992 |
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Growth Inhibitors; H | 1992 |
6 other studies available for suramin and Bone Cancer
| Article | Year |
|---|---|
Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Cell Division; Humans; Osteosarcoma; Su | 2003 |
Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria.
Topics: Bone Neoplasms; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin | 1993 |
Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines.
Topics: Bone Neoplasms; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Osteosarcoma | 1994 |
Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Female; Mice; Mice, Nude; Re | 1998 |
Redundancy of autocrine loops in human osteosarcoma cells.
Topics: Antineoplastic Agents; Autocrine Communication; Becaplermin; Bone Neoplasms; Drug Resistance, Multip | 1999 |
Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Ne | 2001 |